title: Clinical Pharmacokinetics of Dasabuvir.
abstract: Dasabuvir is a nonstructural (NS) 5B non-nucleoside inhibitor of the hepatitis C virus (HCV) used in combination with ombitasvir/paritaprevir/ritonavir for the treatment of chronic HCV infection. It is primarily metabolized by cytochrome P450 (CYP) 2C8, with a minor contribution from CYP3A. Biotransformation of dasabuvir forms the M1 metabolite, which retains antiviral activity. Dasabuvir exhibits linear pharmacokinetics with a terminal half-life of approximately 5-8 h, allowing for twice-daily dosing. The M1 metabolite of dasabuvir is the major metabolite in plasma and has a half-life similar to that of dasabuvir. Dasabuvir exposures in Asian subjects are comparable with Caucasian subjects. The pharmacokinetic characteristics of dasabuvir are similar between healthy subjects and HCV-infected patients, and are not appreciably altered by mild, moderate, or severe renal impairment or dialysis. Dasabuvir pharmacokinetic parameters were not significantly altered in subjects with mild or moderate hepatic impairment; however, exposures were significantly increased in subjects with severe hepatic impairment. Dasabuvir should be administered with food to maximize absorption. Coadministration of dasabuvir with a strong CYP2C8 inhibitor increased dasabuvir exposures by greater than tenfold, whereas coadministration with strong CYP3A inhibitors increased dasabuvir exposures by less than 50%. Furthermore, coadministration of dasabuvir with a CYP3A inducer decreased dasabuvir exposures by 55-70%. Coadministration of dasabuvir with strong CYP2C8 inhibitors or strong CYP3A/CYP2C8 inducers is contraindicated. Results from several drug interaction studies demonstrated that dasabuvir in combination with ombitasvir/paritaprevir/ritonavir can be coadministered with most comedications that are commonly prescribed in HCV-infected patients.
authors.affiliation: Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: King
authors.affiliation: Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.
authors.forename: Jiuhong
authors.initials: J
authors.lastname: Zha
authors.affiliation: Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.
authors.forename: Amit
authors.initials: A
authors.lastname: Khatri
authors.affiliation: Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.
authors.forename: Sandeep
authors.initials: S
authors.lastname: Dutta
authors.affiliation: Clinical Pharmacology and Pharmacometrics, Dept. R4PK, Bldg. AP31-3, AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA. rajeev.menon@abbvie.com.
authors.forename: Rajeev M
authors.initials: RM
authors.lastname: Menon
mesh_terms: D015081:2-Naphthylamine; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D004347:Drug Interactions / Q000502:physiology; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D008107:Liver Diseases / Q000097:blood / Q000188:drug therapy; D013449:Sulfonamides / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics
chemical_list: D000998:Antiviral Agents; D013449:Sulfonamides; D014498:Uracil; D015081:2-Naphthylamine; C588260:dasabuvir
keywords: Breast Cancer Resistance Protein; Hepatic Impairment; Moderate Hepatic Impairment; Severe Hepatic Impairment; Sustained Virologic Response Rate